Surface Oncology Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Surface Oncology Inc
Access all reports
Surface Oncology Inc is a clinical-stage immuno-oncology company dedicated to the development of novel antibody therapies for the treatment of cancer. Its focus lies in creating and advancing treatments designed to modify the tumor microenvironment, thereby supporting and sustaining anti-tumor immune responses. The company's product portfolio includes SRF388, aimed at treating diseases such as renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer, as well as SRF617 for various tumors including gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology is also working on SRF114, NZV930, and GSK4381562 antibodies, alongside conducting research and development activities and pre-clinical studies. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
SURF
Country
🇺🇸 United States